arrow
W

William L. Berry

university of oklahoma health sciences
H指数:42
被引数:7,944

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer

BRG1 (SMARCA4) 状态决定了野生型 EGFR 非小细胞肺癌对 EGFR 抑制剂的反应

Cancers
IF4.4
2026-03-040
OAAI
Corrigendum to “Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer” [Cancer Lett. 2023 Dec 1;578:216437]

勘误:“Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer” [Cancer Lett. 2023 Dec 1;578:216437]

2025-07-020
PRE
FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer

FGF1通过雌激素受体支持内分泌耐药和肥胖相关乳腺癌的糖酵解代谢

2023-08-2211
OAAI
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Pembrolizumab联合多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌患者: 1b/2期主题365队列B研究的长期结果

2022-07-0144
OA
Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
2020-09-013
OAAI